STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
出版年份 2012 全文链接
标题
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
作者
关键词
-
出版物
PLoS One
Volume 7, Issue 2, Pages e30820
出版商
Public Library of Science (PLoS)
发表日期
2012-02-03
DOI
10.1371/journal.pone.0030820
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mutational Status of Myeloproliferative Neoplasms
- (2012) Elisa Rumi et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
- (2012) Andrew Jarnicki et al. Cell Division
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Amplification of chromosomal segment 4q12 in non-small cell lung cancer
- (2010) Alex H. Ramos et al. CANCER BIOLOGY & THERAPY
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
- (2010) K.-F. Chen et al. CLINICAL CANCER RESEARCH
- Janus kinase 2 inhibitors in myeloproliferative disorders
- (2010) Eugenio Lucia et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
- (2010) Young-Kwang Yoon et al. MOLECULAR CARCINOGENESIS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF- IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
- (2010) Z. Yao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
- (2010) I. Astsaturov et al. Science Signaling
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
- (2009) S. Veeriah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
- (2009) D. J. Gough et al. SCIENCE
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started